IL2RB and neoplasm: Using the same 43rd percentile split established for IL2RB expression in the transcriptomics analysis, we observed a trend toward increased PDL1 tumor (Figure 4C, P = 0.058) and ICOS expression (Figure 4D, P = 0.1956) in the IL2RBHi patients.